期刊文献+

受体血清“封闭”供肝与眼镜蛇毒因子抑制异种肝移植超急排斥反应的协同作用 被引量:1

Synergistic effect of donor livers pre-perfused by recipient blood serum and cobra venom factor treatment to inhibit hyperacute rejection happened in liver xenotransplantation
原文传递
导出
摘要 目的探讨受体血清(recipient serum,RS)“封闭”供肝与眼镜蛇毒因子(CVF)抑制肝移植超急性排斥反应(HAR)的协同作用。方法采用改良“双套管法”制作豚鼠→SD大鼠原位肝移植HAR模型。取豚鼠和SD大鼠各24只,分别作为供体和受体。供受体随机配对。移植前采集受体大鼠近交系其他个体血清,灭活补体备用。实验随机分为4组(n=6),受体血清(RS)实验组移植前用0.1oARS的林格氏液(Ringer)“封闭”供肝,CVF实验组受体大鼠在术前24h经尾静脉注射CVF50/μg/kg,另设RS+CVF联合实验组和Ringer液对照组。采用改良“双套管法”行豚鼠→SD大鼠原位肝移植;观察供肝植入后形态学改变、受体存活时间、移植肝病理损害程度和受体肝功能。结果各实验组大鼠异种供肝植入后均未见明显花斑样改变。各实验组大鼠移植后存活时间较对照组[(45.2±13.9)mini均明显延长(P〈O.05),其中RS+CVF组大鼠存活时间[(161.5±30.9)mini长于RS组[(88.1±19.7)mini(P〈0.01)或CVF组[(125.2±25.5)mini(P%0.05)。各实验组大鼠血清丙氨酸转氨酶(ALT)均明显低于对照组[(126.1±23.3)U/L3(P〈0.05),RS+CVF组ALT[(63.2±13.9)U/L3明显低于CVF组[(79.9±18.1)u/L](P〈O.05)或RS组[(106.1±19.3)U/L](P〈0.01)。各实验组移植肝血栓、出血、水肿等病理损害(积分)均较对照组明显减轻(P〈O.05),其中RS+CVF组大鼠移植肝病理损害最轻(P〈0.05)。结论受体血清“封闭”供肝与CVF对肝移植HAR均具有一定的抑制作用,两者具有协同作用。 Objective To investigate synergistic effect of donor livers blocked by recipient blood serum (RS) and cobra venom factor (CVF) treatment to inhibit hyperacute rejection (HAR) happened in liver xenotransplantation. Methods The SD rat blood serum was prepared for pre-perfusing the do-nor livers before experiment. 24 pairs of guinea-pig (GP) and Sprague-Dawley (S. D. ) rats were choiced respectively and pair-matched between GP donor and rat recipient randomly. Before transplan-tation, donor livers of GPs were pre-perfused by 0.5 % SD rat serum. Paired animals were divided into 4 groups randomly such as donor liver perfused by RS, recipient treated by CVF, RS+ CVF per-formed and Ringer solution as a control. The orthotopic liver xenotransplantations was performed with two-cuff technique. The survival time and liver function of recipients, morphological and pathological changes of rat livers were observed. Results There was no piebaldism change on the recipient liver from experimental group. The survival time of recipients from RS+CVF group [(161.5±30.9) mini was longer than that of control[(45.2±13. 9) mini and CVF[(125.2±25. 5) mini or RS groups [(88.1±19.7) mini (P〈0.05). The ALT in serum of recipients from RS+CVF [(63.2±13.9)U/L] was lower than that from congtrol group [(126.±23.3)U/L](P〈0.01) and CVF group [(79.9± 18.1)U/L](P〈0.05) or RS group [(106.1±19.3)U/L](P〈0.01) The histological damages inclu-ding thrombosis, interstitial bleeding and edema of recipient liver from RS+CVF group were allevia-ted markebly than that of other groups (P〈0.05). Conclusion There was a synergistic effect to in-hibit HAR happened in liver xenotransplantation by blocking the donor liver with recipient blood ser-um and CVF treatment significantly.
出处 《中华肝胆外科杂志》 CAS CSCD 北大核心 2012年第5期377-380,共4页 Chinese Journal of Hepatobiliary Surgery
基金 广东省自然科学基金(06301453)
关键词 受体血清 异种肝移植 CVF 超急性排斥反应 Recipient blood serum Liver xenotransplantation Cobra venom factor H y-peracute rejection
  • 相关文献

参考文献7

二级参考文献38

  • 1王滔,夏穗生.中华眼镜蛇蛇毒对大鼠异种心脏移植超急性排斥反应的影响[J].中华器官移植杂志,1997,18(1):22-24. 被引量:7
  • 2Volpin R,Angeli P,Galioto A,et al.Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients:a controllej clinical trial.Liver Transpl,2002,8:527-534.
  • 3Andreu H,Rimola A,Bruguera M,et al.Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression:predictive factors of response to antirejection therapy.Transplantation,2002,73:1936-1943.
  • 4Tippner C,Nashan B,Hoshino K,et al.Clinical and subclinical acute rejection early after liver transplantation contributing factors and relevance for the long-term course.Transplantation,2001,72:1122-1128.
  • 5Israeli M,Klein T,Sredni B,et al.ImmuKnow:a new parameter in immune monitoring of pediatric liver transp 1 antationrecipients.Liver Transpl,2008,14:893-898.
  • 6Israeli M,Yussim A,Mor E,et al.Preceeding the rejection:in search for a comprehensive post-transplant immune monitorring platform.Transpl Immunol,2007,18:7-12.
  • 7Bhorade SM,Janata K,Vigneswaran WT,et al.Cylex ImmuKnow assay levels are lower in lung transplant recipient with infection.J Heart Lung Transplant,2008,27:990-994.
  • 8An International Panel.Banff schema for grading liver allograft rejection:an international consensus document.Hepatology,1997,25:658-663.
  • 9Venkataraman R,Shaw LM,Sarkozi L,et al.Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients.J Clin Pharm,2001,41:542.
  • 10Rovira P,Mascarell L,Truffa-Bachi P.The impact of immune suppressive drugs on the analysis of T cell activation.Curr Med Chem,2000,7:673.

共引文献22

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部